Mercy Expands AI-Driven Smart-Texting Program for Chemotherapy Patients

Mercy Expands AI-Driven Smart-Texting Program for Chemotherapy Patients

Mercy has received funding from the Patient-Centered Outcomes Research Institute to expand its AI-driven smart-texting program to all chemotherapy patients aged 18 and up.

Mercy has been awarded a four-year funding grant from the Patient-Centered Outcomes Research Institute (PCORI) to expand its AI-driven smart-texting program. This initiative, announced in a press release, will extend the program's reach to all chemotherapy patients aged 18 and older, enhancing the existing electronic patient-reported monitoring platform.

The expansion will not only broaden the age group but also include additional health areas such as physical function, behavioral health, and health-related social needs. The program will also incorporate automated phone systems and MyMercy messages for patients who do not respond to text messages.

The project builds on findings from a PCORI-funded study that demonstrated improved symptom control and quality of life for patients using electronic patient-reported outcome surveys. The expanded program is expected to be available to patients by October 2026.

We hope you enjoyed this article.

Consider subscribing to one of several newsletters we publish. For example, in the Daily AI Brief you can read the most up to date AI news round-up 6 days per week.

Also, consider following us on social media:

Subscribe to Daily AI Brief

Daily report covering major AI developments and industry news, with both top stories and complete market updates